The use of mycophenolate mofetil(cellcept)in renal transplantation

Nephron

Volumn 76, Issue 4, 1997, Pages 392-399

  Vanrenterghem, Y ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Immunosuppression; Purine synthesis; Rejection; Renal transplantation

Indexed keywords

CYCLOSPORIN A; GUANINE NUCLEOTIDE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CELL DIVISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PURINE SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VIRUS INFECTION;

EID: 0030797261     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000190219     Document Type: Article

References (31)

1. Opclz G for the Collaborative Transplant Study: Collaborative Transplant Study - 10-year report, Transplant Proc 1992:24:2342- 2355.
2. European Multicentre Trial Group: Cyclosporin in cadaveric renal transplantation: One-year follow-up of a multiccntrc trial, Lancet 1983;2: 986-989.
3. Thiel G, Harder F, Lörtschcr R, ßrünisholz, M, Landmann J, Brunner F, Follath F, Wenk M, Mihatsch M: Cyclosporin A used alone or in combination with low-dose steroids in cadaveric renal transplantation, Klin Wochenschr 1983;61:991-1000.
4. Lindholm A, Ohlman S, Albrechtsen D, Tufve-son G, Persson H, Persson NH: The impact of acute rejection episodes on long-term graft function and outcome in 1.347 primary renal transplants treated by three cyclosporinc regimens, Transplantation 1993:56:307-315.
5. Gulanikar AC, McDonald AS, Sungertekin U, Belitsky P: The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants, Trans-plantation 1992:53:232-328.
6. Vanrcnterghent YFCh: Acute rejection and renal allograft outcome, Nephrol Dial Transplant 1994;10(suppl 1):29-31.
7. Terasaki PI, Yuge J, Cccka JM, Gjertson DW, Takemoto S, Clio Y: Thirty-year trends in clinical kidney transplantation: in Terasaki PI, Cccka JM (eds): Clinical Transplants 1993. Los Angeles, UCLA Tissue Typing Laboratory, 1994. pp 553-563.
8. Sweeney MJ: Mycophenolic acid and its mechanism of action in cancer and psoriasis, Jpn J Antibiot 1977;30(suppl):85-92.
9. Allison AC, Eugui EM: The design and the development of an immunosuppressive drug, Mycophenolate Mofetil, Springer Semin Im-munopathol 1993;14:353-380.
10. Allison AC, Hovi T, Watts RWE, Webster ADB: Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of dc novo purine synthesis in lymphocyte transformation, Lancet 1975;2: 1179-1182.
11. Lee WA, Gu L, Kiksztal AR, Chu N, Leung K, Nelson PH: Bioavailability improvement of mycophenolic acid through aminoester deriva-tization, Pharm Res 1990;7:161-166.
12. Sweeney MJ, Hoffman DH, Esterman MA: Metabolism and biochemistry of mycophenolic acid, Cancer Res 1972:32:1803-1809.
13. Franklin TJ, Cook JM: The inhibition of nucleic acid synthesis by mycophenolic acid, Bio-ehemJ 1969;1 13:515-524.
14. Natsumeda Y, Carr SF: Human type I and 11 IMP dehydrogenases as drug targets, Ann NY AcadSci 1993;696:88-93.
15. Allison AC, Eugui EM: Preferential suppression of lymphocyte proliferation by mycophe-nola:c acid and predicted long-term effects of Mycophenolate Mofetil in transplantation, Transplant Proc 1994:26:3205-3210.
16. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of Mycophenolate Mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection, Lancet 1995:345:1321-1325.
17. Sollingcr HW for the US Renal Transplant Mycophenolate Mofetil Study Group: Mycophe-nola', e Mofetil for the prevention of acute rejec-tion in primary cadaveric renal allograft recipients, Transplantation 1995:60:225-232.
18. The Tricontinental Mycophenolate Mofetil Renal Transplant Trial Study Group: A blinded, randomized clinical trial of Mycophenolate Mofetil for the prevention of acute rejection in cadaveric renal transplantation, Transplantation 1996:61:1029-1037.
19. Sollingcr HW, Beizer FO, Deierhoi MH, Diet-lclm AG, Gonwa TA, Kavffman RS, Klinthalm GB, McDiarmid SV, Roberts J, Rosenthal JT, Tomlanovich SJ: RS-61443 (Mycophenolate Mofetil): A multiccnter study for refractory kidney transplant rejection, Ann Surg 1992: 216:513-519.
20. The Mycophenolate Mofctil Renal Refractory Rejection Study Group: Mycophenolate Mofe-til for the treatment of refractory, acute, cellular renal transplant rejection, Transplantation 1996:61:722-729.
21. Klintmalm GB, Ascher NL, Busuttil RW, Deierhoi M, Gonwa TA, Kauffman R, McDiarmid S, Poplawski S, Sollinger H, Roberts J: RS-61443 for treatment-resistant human liver rejection, Transplant Proc 1993:25: 679.
22. Kirklin JK, Bourge RC, Naftel DC, Morrow WR, Deierhoi MIC KaulTman RS, White-Wil-Iiams C, Nombergg RI, Holman WL, Smith DC: Treatment of recurrent heart rejection with Mycophenolate Mofctil (RS-61443): Initial clinical experience, J Heart Lung Transplant 1994:13:444-450.
23. Opclz G, Henderson R: Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients, Lancet 1993:2: 1514-1516.
24. Hanto DW, Frizzcra G, Gajl-Pcczalska KJ, Simmons RL: Epstcin-Barr virus, immunodeficiency, and B cell lymphoprolifcration, Transplantation 1985;39:461-472.
25. Azuma H, Binder J, Hecmann U, Schmid C, Tullius SG, Tilney NL: Effects of RS-61443 on functional and morphological changes in chronically rejecting rat kidney allografts, T ransplantation 1995:59:460-466.
26. O’Hair DP, McManus RP, Komorowski R: Inhibition of chronic rejection in primate cardiac xenografts using Mycophenolate Mofetil, Ann Thorac Surg 1994:58:1311-1313.
27. Allison AC, Kowalski WJ, Muller CD, Eugui EM: Mechanism of action of mycophenolic acid, Ann NY Acad Sei 1993.696:63-87.
28. Allison AC, Eugui EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, Mycophenolate Mofetil, Immunol Rev 1993;136:5-28.
29. Morrs RE, Hoyt EG, Murphy MP, Eugui EM, Alliscn AC: Mycophenolic acid morpholino-cthylestcr (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T and B cell purine synthesis, Transplant Proc 1990:22: 1659-1662.
30. Parker G, Bullingham R, Kamm B, Hale M: Pharmacokinetics of oral Mycophenolate Mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment, J Clin Pharmacol 1996:36:332-336.
31. Bullingham R, Monroe S, Nicholls A, Hale M: Pharmacokinetics and bioavailability of Myco-phcnolatc Mofetil in healthy subjects after sin-gle-doscoral and intravenous administration, J Clin Pharmacol 1996:36:315-324.